It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The mechanisms of the natural product dioscin against non-alcoholic fatty liver disease (NAFLD) are unclear. Thus, the purpose of the present study was to further confirm its effects of prevention and then to elucidate the potential mechanisms underlying its activity in mice. High-fat diet (HFD)-induced C57BL/6J mice and ob/ob mice were used as the experimental models. Serum and hepatic biochemical parameters were determined and the mRNA and protein expression levels were detected. The results indicated that dioscin alleviated body weight and liver lipid accumulation symptoms, increased oxygen consumption and energy expenditure and improved the levels of serum and hepatic biochemical parameters. Further investigations revealed that dioscin significantly attenuated oxidative damage, suppressed inflammation, inhibited triglyceride and cholesterol synthesis, promoted fatty acid β-oxidation, down-regulated MAPK phosphorylation levels and induced autophagy to alleviate fatty liver conditions. Dioscin prevents diet induced obesity and NAFLD by increasing energy expenditure. This agent should be developed as a new candidate for obesity and NAFLD prevention.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 College of Pharmacy, Dalian Medical University, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426)
2 College of Pharmacy, Dalian Medical University, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426); Research Institute of Integrated Traditional and Western Medicine of Dalian Medical University, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426)